DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration
Silver Spring MD 20993

NDA 020505/S-050
NDA 020844/S-041

SUPPLEMENT APPROVAL

Janssen Pharmaceuticals, Inc.
c/o Janssen Research & Development, LLC
Attention: Christine Grundy, PharmD
Associate Director, Regulatory Affairs
1125 Trenton-Harbourton Road, P.O. Box 200
Titusville, NJ 08560-0200

Dear Dr. Grundy:

Please refer to your Supplemental New Drug Applications (sNDAs) submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for the following:

Application	Drug Product	Submitted on:	Received on:
NDA 020505/S-050	Topamax (topiramate) Tablets (25mg, 50mg, 100mg, and 200mg)	01/19/2012	01/19/2012
NDA 020844/S-041	Topamax (topiramate) Sprinkle Capsules (15mg, and 25mg)		
These "Changes Being Effected" supplements provide for:			
• Revision to section 17.2 Patient Counseling Information and Medication Guide, informing patients that they should contact their healthcare professional immediately if they experience symptoms related to oligohidrosis or hyperthermia.			

We acknowledge your electronic agreements to amend section 5.9 as follow:

Application	Agreement to amend Dated:
NDA 020505/S-050 NDA 020844/S-041	April 4, 2012, and August 3, 2012
These "Changes Being Effected" supplement provide for:	
• Revision to section 5.9 of the Warnings and Precautions by adding "Topamax with concomitant VPA" to convey that the hyperammonemia developed in response to treatment with both Topamax and VPA together	

We have completed our review of these supplemental applications, as amended. These supplemental applications are approved, effective on the date of this letter, for use as recommended in the enclosed, agreed-upon labeling text.

CONTENT OF LABELING

We also refer to our electronic agreement for you to update the content of CBE during your next NDA annual report in November 2012.

As soon as possible, but no later than 14 days from the date of submission of the new label with your annual report in November of 2012, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm. Content of labeling must be identical to the enclosed labeling (text for the package insert, Medication Guide), with the addition of any labeling changes in pending "Changes Being Effected" (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

Information on submitting SPL files using eLIST may be found in the guidance for industry titled "SPL Standard for Content of Labeling Technical Qs and As" at http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf.

The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in MS Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes and annotate each change. To facilitate review of your submission, provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

PROMOTIONAL MATERIALS

You may request advisory comments on proposed introductory advertising and promotional labeling. To do so, submit the following, in triplicate, (1) a cover letter requesting advisory comments, (2) the proposed materials in draft or mock-up form with annotated references, and (3) the package insert(s) to:

Food and Drug Administration
Center for Drug Evaluation and Research
Office of Prescription Drug Promotion (OPDP)
5901-B Ammendale Road
Beltsville, MD 20705-1266

You must submit final promotional materials and package insert(s), accompanied by a Form FDA 2253, at the time of initial dissemination or publication [21 CFR 314.81(b)(3)(i)]. Form FDA 2253 is available at http://www.fda.gov/opacom/morechoices/fdaforms/cder.html; instructions are provided on page 2 of the form. For more information about submission of promotional materials to the Office of Prescription Drug Promotion (OPDP), see http://www.fda.gov/AboutFDA/CentersOffices/CDER/ucm090142.htm.

All promotional materials that include representations about your drug product must be promptly revised to be consistent with the labeling changes approved in this supplement, including any new safety information [21 CFR 314.70(a)(4)]. The revisions in your promotional materials should include prominent disclosure of the important new safety information that appears in the revised package labeling. Within 7 days of receipt of this letter, submit your statement of intent to comply with 21 CFR 314.70(a)(4) to the address above or by fax to 301-847-8444.

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Su-Lin Sun, PharmD, Regulatory Project Manager, at (301) 796-0036 or email su-lin.sun@fda.hhs.gov .

Sincerely,

{See appended electronic signature page}

Russell G. Katz, M.D.
Director
Division of Neurology Products
Office of Drug Evaluation I
Center for Drug Evaluation and Research

ENCLOSURE:
Content of Labeling

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

RUSSELL G KATZ
10/29/2012